Research overview · PCC1

Procyanidin C1 and the senescence question.

An evidence-led introduction to PCC1, a naturally occurring procyanidin being studied for its potential to modulate - and in experimental settings, selectively target - senescent cells.

Explore the science

What the research asks

Can we reduce the burden of senescent cells without losing their useful roles?

Cellular senescence is a lasting pause in cell division triggered by stress or damage. It can be protective in the short term. Over time, however, accumulating senescent cells may produce inflammatory signals - often grouped as the senescence-associated secretory phenotype (SASP) - that researchers are investigating across ageing biology.

01 · CONTEXT

Senescent burden

Senescent cells may remain metabolically active while releasing signalling molecules that can influence neighbouring tissues.

02 · APPROACH

Senolytics & senomorphics

Senolytics are designed to eliminate selected senescent cells; senomorphics seek to change harmful signalling without necessarily removing the cells.

03 · RESEARCH FOCUS

PCC1

PCC1 is a B-type procyanidin trimer found in botanical sources including grape seed. Its concentration-dependent effects are being explored in cell and animal models.

A dose-dependent hypothesis

Two modes under investigation.

The source document describes a research hypothesis in which PCC1 may show different activity at different experimental concentrations. This is not a dosing recommendation and does not establish human benefit.

Senomorphic investigation

At lower experimental concentrations, researchers have explored whether PCC1 can alter SASP-associated inflammatory signalling.

Senolytic investigation

At higher experimental concentrations, preclinical research has explored whether PCC1 can preferentially induce death in certain senescent-cell models.

Experimental concentration ranges and preclinical mechanisms do not translate directly into safe or effective human use.

What has been studied

Signals across several research models.

The research deck surveys findings in cellular and animal models related to fibrosis, retinal biology, inflammation, metabolism, and cancer-cell systems. These are separate experimental contexts; they do not demonstrate that PCC1 prevents, treats, or cures any human disease.

A responsible research programme separates biological promise from clinical proof.

EVIDENCE STATUS

Preclinical and translational

Much of the PCC1 literature concerns laboratory, cell, or animal research. Human evidence requires rigorous, independently reported clinical studies with verified safety, formulation, exposure, and outcomes.

From research to clinic

What must happen next.

The source document correctly identifies delivery, formulation, metabolism, dose, timing, and human validation as central translational questions. Astra treats these as requirements - not conclusions.

1Dose & timing

Define exposure and schedule in properly designed studies.

2Mechanism

Clarify targets, selectivity, and potential off-target effects.

3Human validation

Establish safety and clinically meaningful outcomes in registered trials.

4Formulation & metabolites

Characterise oral bioavailability, metabolism, and tissue exposure.

Important research notice. PCC1 is not an approved treatment for ageing, cancer, fibrosis, eye disease, diabetes, or any other condition. Statements on this page describe research questions and preclinical findings only. They are not medical advice, treatment claims, or a substitute for care from a qualified healthcare professional.

Reading the evidence

Source & further reading.

This page was structured from the supplied PCC-1 explained research deck and calibrated to distinguish claims reported in that deck from established clinical evidence.

Primary preclinical reference: Xu et al., “Procyanidin C1 is a natural senolytic agent that selectively eliminates senescent cells in vitro and improves physical function and increases survival in mice,” Nature Metabolism (2021).

View the PubMed record ↗